Приказ основних података о документу
Production routes of the alpha emitting Tb-149 for medical application
dc.creator | Beyer, GJ | |
dc.creator | Čomor, Jožef J. | |
dc.creator | Dakovic, M | |
dc.creator | Soloviev, D | |
dc.creator | Tamburella, C | |
dc.creator | Hagebo, E | |
dc.creator | Allan, B | |
dc.creator | Dmitriev, SN | |
dc.creator | Zaitseva, NG | |
dc.creator | Starodub, GY | |
dc.creator | Molokanova, LG | |
dc.creator | Vranješ, Sanja | |
dc.creator | Miederer, M | |
dc.creator | ISOLDE Collaboration | |
dc.date.accessioned | 2018-03-01T19:06:18Z | |
dc.date.available | 2018-03-01T19:06:18Z | |
dc.date.issued | 2002 | |
dc.identifier.issn | 0033-8230 | |
dc.identifier.uri | https://vinar.vin.bg.ac.rs/handle/123456789/2520 | |
dc.description.abstract | The partial alpha emitting lanthanide isotope Tb-149 seems to have a great potential in systemic radioimmuno therapy (RIT), especially when single cells in transit or circulation are targeted. The isotope Tb-149 has a half life of 4.118h and decays by alpha emission (3.97MeV, 17%) EC-process (76%) and beta(+)-emission (7%). In this paper. we analyze the possible production routes: light- and heavy ion induced nuclear reactions and p-induced spallation. The excitation functions for light- and heavy ion induced reactions have been calculated using the ALICE91 code. The direct nuclear reaction Gd-152 (p, 4n) Tb-149 was found to be the most promising production path. Alternatively, the indirect reaction Nd-142 (C-12 5n) Dy-149 -- GT Tb-149 seems to be much more suitable compared to the reaction on the mono-isotopic target element Pr-141 (C-12, 4n) Tb-149. In this case, both, the production yield of Tb-149 and the radionuclidic purity are considerably lower, compared to the (p, 4n)-reaction. In preliminary experiments we produced Tb-149 via the indirect reaction Nd (C-12, 5n) Dy-149 -- GT Tb-149 (108 MeV C-12(+6) ions and 1 particle-muA) at the U-200 heavy ion cyclotron at the FLNR of the JINR Dubna. From a 1.25 It irradiation of a 12 mg/cm(2) (Nd2O3)-Nd-nat target, we obtained 2.7 MBq of Tb-149 (70 muCi) at 20 min EOB. This allows the conclusion, that a dedicated cyclotron equipped with a modem ECR-ion source, providing high ion currents would allow the continuous production of batches of the order of 10-20 GBq of Tb-149 for routine RI-therapy. The lower cross section of the spallation process can be compensated by using very thick targets. On-line mass separation technique provides high purity isotopically clean Tb-149 preparations, independently on the production route chosen. At the ISOLDE facility at CERN, we prepared batches of up to 500 MBq Tb-149 by combining on-line mass separation process followed by a cation exchange chromatography process using alpha-HIBA as eluent. The obtained Tb-149 preparations showed excellent behavior in labeling of chelated monoclonal antibodies. | en |
dc.rights | restrictedAccess | en |
dc.source | Radiochimica Acta | en |
dc.subject | medical radionuclide production | en |
dc.subject | therapeutic radionuclides | en |
dc.subject | spallation production | en |
dc.subject | heavy ion induced nuclear reaction | en |
dc.subject | Tb-149 | en |
dc.title | Production routes of the alpha emitting Tb-149 for medical application | en |
dc.type | article | en |
dcterms.abstract | Беyер, ГЈ; Цомор, ЈЈ; Даковиц, М; Тамбурелла, Ц; Хагебо, Е; Aллан, Б; Дмитриев, СН; Заитсева, НГ; Стародуб, ГY; Молоканова, ЛГ; Врањес, С; Миедерер, М; ИСОЛДЕ Цоллаборатион; Соловиев, Д; | |
dc.citation.volume | 90 | |
dc.citation.issue | 5 | |
dc.citation.spage | 247 | |
dc.citation.epage | 252 | |
dc.identifier.wos | 000175861100001 | |
dc.identifier.doi | 10.1524/ract.2002.90.5_2002.247 | |
dc.citation.rank | M22 | |
dc.identifier.scopus | 2-s2.0-0036428425 |
Документи
Датотеке | Величина | Формат | Преглед |
---|---|---|---|
Уз овај запис нема датотека. |